There are 2789 resources available
1190TiP - SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Presenter: Rafal Dziadziuszko
Session: ePoster Display
1195P - Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
Presenter: Sanjay Popat
Session: ePoster Display
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1197P - First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Presenter: Qing Zhou
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display
1199P - Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display